Press release - 04/11/2010 LifeCodexx Appoints Head of Commercial Operations Dr. Martin Burow, a proven expert in the field of prenatal diagnostics, has joined the LifeCodexx team as Head of Commercial Operations.https://www.gesundheitsindustrie-bw.de/en/article/press-release/lifecodexx-appoints-head-of-commercial-operations
Article - 25/10/2010 Angelika Rück visualises the dance of molecules Angelika Rück measures the luminescence time of molecules in order to find out whether proteins are speaking with each other. She hopes that she will soon be able to differentiate inflammation from tumours. Rück who is head of microscopy at the Ulm-based ILM has worked hard with her colleagues to make the Eselsberg-based Ulm University location one of southern Germanys leading life cell imaging centres.https://www.gesundheitsindustrie-bw.de/en/article/news/angelika-rueck-visualises-the-dance-of-molecules
Article - 18/10/2010 DNA analysis is becoming more automated GATC Biotech AG is already on the lookout for next generation sequencing technologies in the form of real-time single-molecule sequencing. In an interview with BIOPRO Thomas Pohl CTO of GATC Biotech AG explains why the company is continuously expanding its existing equipment with the latest global technologies.https://www.gesundheitsindustrie-bw.de/en/article/news/dna-analysis-is-becoming-more-automated
Dossier - 18/10/2010 New machines for the life sciences Hardware and software applications have become an integral part of the everyday life of life sciences researchers, developers and service providers. It is impossible to imagine life science applications without effective hardware and software applications – from computer-assisted drug screening to the automatic production of biosensors for rapid, mobile, purse-size bacterial test devices. Trends such as automation and miniaturisation lead to ever…https://www.gesundheitsindustrie-bw.de/en/article/dossier/new-machines-for-the-life-sciences
Press release - 13/10/2010 GATC Biotech to be First European Service Provider for the PacBio RS GATC Biotech announced today that it has agreed to purchase the PacBio RS platform, a single molecule, real-time (SMRT™) sequencing technology. The new PacBio RS will be the fifth sequencing technology for GATC Biotech. The system is planned for installation in early 2011.https://www.gesundheitsindustrie-bw.de/en/article/press-release/gatc-biotech-to-be-first-european-service-provider-for-the-pacbio-rs
Article - 04/10/2010 Dr. Kerstin Stemmer: important approaches for the early identification of carcinogenic substances Dr. Kerstin Stemmer from the University of Konstanz has found a way to identify the carcinogenic potential of substances in just a few days using state-of-the-art technology and new investigation methods. This is the first time that researchers have been able to reduce the time and the number of animals used in carcinogenesis studies.https://www.gesundheitsindustrie-bw.de/en/article/news/dr-kerstin-stemmer-important-approaches-for-the-early-identification-of-carcinogenic-substances
Press release - 21/09/2010 The National Cohort study The objective of the National Cohort study, the largest prospective study ever conducted in Germany, is to provide answers to a broad range of epidemiological questions, to identify risk factors for common diseases and to open up new treatment pathways. This project is being planned since beginning 2009 by the health centers of the Helmholtz Association in a network with partners from universities and other public research institutions.https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-national-cohort-study
Dossier - 20/09/2010 Neurodegenerative diseases It is estimated that around 1.2 million people in Germany suffer from dementia, and around 200,000 people are diagnosed with neurodegenerative diseases every year. It is expected that by 2050, one in three people in Germany will be over 60 and the number of age-related diseases, particularly dementias, for which no effective curative therapy is currently available, will increase considerably. Given the large numbers of elderly people and…https://www.gesundheitsindustrie-bw.de/en/article/dossier/neurodegenerative-diseases
Article - 20/09/2010 BioFluidix GmbH – the smallest droplets for research and industry The experts at Freiburg-based BioFluidix GmbH specialise in what is known as microfluidics. The company offers solutions for the non-contact dispensing of liquids in the range of a few nanolitres up to several microlitres. These microfluidic devices are used for lab-on-the-chip applications that integrate one or several laboratory steps on a single chip. BioFluidix GmbH a spin-off of the University of Freiburg and member of the MicroTEC Südwest…https://www.gesundheitsindustrie-bw.de/en/article/news/biofluidix-gmbh-the-smallest-droplets-for-research-and-industry
Article - 13/09/2010 Sven Perner: a pathologist with the courage to carry out interdisciplinary research Dr Sven Perner from Tuebingen was recently awarded the newly created Württemberg Cancer Prize for his work that has made decisive contributions to the understanding of prostate cancer development. In addition the identification of a tumour-specific gene fusion might also be of great importance for other types of cancer. https://www.gesundheitsindustrie-bw.de/en/article/news/sven-perner-a-pathologist-with-the-courage-to-carry-out-interdisciplinary-research
Article - 30/08/2010 More effective prevention and treatment of diabetic feet Dr. med. dent. Hans-Helmut Schmidt has developed a device that enables the effective and hygienic treatment of patients with diabetic foot syndrome DFS. The new device known as DIAPEDES enables diabetic feet to be treated in a closed foot-shaped container under definite clinical conditions. Diabetic feet can smell and look quite unpleasant and the preventive care that this device will offer for many users has been developed with this problem in…https://www.gesundheitsindustrie-bw.de/en/article/news/more-effective-prevention-and-treatment-of-diabetic-feet
Article - 30/08/2010 Diagnostics for the early detection of cervical cancer The Pap test is regarded as the most successful test for cancer ever, and has saved the lives of many women. However, the test is associated with several weaknesses. The Heidelberg-based in vitro diagnostics company mtm laboratories AG develops and commercialises highly sensitive and highly specific immunochemical tests that provide greater reliability. These tests have the potential to revolutionise the early detection of cervical cancer.https://www.gesundheitsindustrie-bw.de/en/article/news/diagnostics-for-the-early-detection-of-cervical-cancer
Article - 30/08/2010 A centre focusing on hepatocellular carcinoma research Under its director, Prof. Dr. Peter Schirmacher, the Institute of Pathology at the University of Heidelberg has become a major liver cancer research centre, with a particular focus on hepatocellular carcinoma. The institute is looking for new diagnostic markers and new molecular targets for drugs that have the potential to be used for specifically treating this cancer. https://www.gesundheitsindustrie-bw.de/en/article/news/a-centre-focusing-on-hepatocellular-carcinoma-research
Article - 30/08/2010 Bodensee Brustzentrum offers effective breast cancer prevention services The two Brustzentrum Bodensee (Lake Constance Breast Centre) sites at the Hospital in Constance and the Women’s Hospital in Friedrichshafen have a principal goal: to enable the best possible early detection of all types of breast cancer, to reduce the morbidity and mortality of breast cancer patients and to increase survival rates by offering ultra-modern breast cancer prevention measures. https://www.gesundheitsindustrie-bw.de/en/article/news/bodensee-brustzentrum-offers-effective-breast-cancer-prevention-services
Article - 30/08/2010 Genetic testing for the prevention of diseases? Genetic testing is beginning to play an important role in personalised medicine and is indispensable for the diagnosis and therapy of many diseases. However, the preventive and diagnostic power of many genetic tests is still inferior to traditional diagnostic tests. In addition, commercial genetic tests do not always live up to the claims made about them. https://www.gesundheitsindustrie-bw.de/en/article/news/genetic-testing-for-the-prevention-of-diseases
Dossier - 30/08/2010 Disease prevention through better diagnostics “Classical treatment approaches are not the only way to ensure good health, rehabilitation and care. In fact, it is envisaged that more effective prevention will contribute to halting the development of diseases and maintaining good health. Prevention is designed to prevent health risks and diseases, make them less likely and delay their onset.” (Declaration of the German government; Official Records of Parliament 17/845, 26th February 2010) https://www.gesundheitsindustrie-bw.de/en/article/dossier/disease-prevention-through-better-diagnostics
Article - 09/08/2010 Quick and early detection of rare diseases Lysosomal storage diseases LSD are a group of around 50 rare inherited metabolic disorders. Only 12 LSDs have been described biochemically and microbiologically. Prof. Dr. Michael Przybylski from the Steinbeis Transfer Centre for Biopolymer Analysis and Proteomics at the University of Constance now hopes to change this situation. In a project carried out in cooperation with the biotech company Genzyme CEE Konstanz and the University of Timisoara…https://www.gesundheitsindustrie-bw.de/en/article/news/quick-and-early-detection-of-rare-diseases
Press release - 05/07/2010 AnDiaTec - Real cowboys have heard of Kornwestheim AnDiaTec GmbH & Co. KG from Kornwestheim is in high demand worldwide as a partner specialising in detection methods for bacteria and viruses. The company is a world market leader in real time PCR Kits for the detection of noroviruses. The U.S. Ministry of Agriculture even draws on the expertise of AnDiaTec in relation to virus infections in cattle. After an intensive period of research and development, the company is now expanding its sales…https://www.gesundheitsindustrie-bw.de/en/article/press-release/andiatec-real-cowboys-have-heard-of-kornwestheim
Article - 28/06/2010 ATG:biosynthetics GmbH – Modular molecular systems of the future ATGbiosynthetics GmbH based in Merzhausen close to Freiburg produces biological systems that can combine gene constituents following a construction kit principle. The company provides the pharmaceutical industry and basic researchers with products that have specifically chosen properties.https://www.gesundheitsindustrie-bw.de/en/article/news/atg-biosynthetics-gmbh-modular-molecular-systems-of-the-future
Press release - 24/06/2010 febit Announces Operational Restructuring febit today announced a restructuring as a consequence of its strategic focus on blood-based microRNA biomarker discovery febits major business development in 20092010 and on partnerships and intellectual property IP commercialization. The new focus includes the collaboration and provision of high-end services for clinical researchers in academia diagnostic companies and the pharma industry. The operational restructuring resulted in a reduction…https://www.gesundheitsindustrie-bw.de/en/article/press-release/febit-announces-operational-restructuring
Article - 07/06/2010 Biametrics – specialist in label-free bioanalysis Biametrics is a spin-off from the University of Tübingen that focuses on the commercialisation of innovative developments in the field of label-free bioanalyses. The companys platform detects interactions between biomolecules using reflectometric interference spectroscopy RIfS and can be integrated into small mobile analytical devices.https://www.gesundheitsindustrie-bw.de/en/article/news/biametrics-specialist-in-label-free-bioanalysis
Press release - 07/06/2010 Addition of renowned experts to Medical Advisory Board and achievement of international quality standards generate added optimism With a € 1.5 Mio Second Closing, Curetis has now increased its Series A financing round to € 20 Mio. This additional financing will enable Curetis to complete the development of its innovative diagnostic products through to market entry. Quality Certification for its diagnostic product development represents an additional milestone in Curetis' commercial strategy. At the same time, Curetis has added internationally recognized expertise in…https://www.gesundheitsindustrie-bw.de/en/article/press-release/addition-of-renowned-experts-to-medical-advisory-board-and-achievement-of-international-quality-stan
Press release - 21/05/2010 The fingerprints of molecules Prof. Heiko Möller is head of the NMR Core Facility a centre at the University of Constance that focuses on magnetic resonance spectroscopy where fingerprints of molecules are taken. The highly sensitive analysis instruments are used by his group of researchers for research projects on subjects ranging from severed visual nerves cancer protection and the rapid identification of anthrax bacteria.https://www.gesundheitsindustrie-bw.de/en/article/press-release/the-fingerprints-of-molecules
Article - 10/05/2010 CeGaT: DNA and RNA sequencing specialist Sequencing service providers are facing new challenges due to the enormous technological progress made in this field. The market requires technically feasible solutions reliable and rapid sequence analyses in which entire genomes can be analysed within a couple of days or weeks. This can only be achieved with state-of-the-art high-throughput technologies. Tübingen-based CeGaT GmbH has been offering DNA and RNA sequencing using state-of-the-art…https://www.gesundheitsindustrie-bw.de/en/article/news/cegat-dna-and-rna-sequencing-specialist
Article - 07/05/2010 Günter Gauglitz: research at the boundaries of physics, chemistry and biology Biosensors and label-free optical bioanalysis are the major research priorities of Prof. Dr. Günter Gauglitz from the Institute for Physical and Theoretical Chemistry IPC at the University of Tübingen. His whole career has been about the acquisition of multi-million third-party funded projects that are worked on by a team of 15 scientists at the IPC.https://www.gesundheitsindustrie-bw.de/en/article/news/guenter-gauglitz-research-at-the-boundaries-of-physics-chemistry-and-biology
Press release - 06/05/2010 Second Biomarker Expert Meeting in Heidelberg Numerous experts in molecular diagnostics convened at the Second Workshop of the Biomarker Discovery Center (BDC) in Heidelberg. More than 40 researchers from universities, hospitals and industry from various regions of Germany made their way to the city despite adverse travel conditions caused by the volcanic ash cloud.https://www.gesundheitsindustrie-bw.de/en/article/press-release/second-biomarker-expert-meeting-in-heidelberg
Press release - 23/04/2010 International Cancer Genome Project Publishes Article in Nature Information obtained in the various projects of the International Cancer Genome Consortium may soon be used to the benefit of cancer patients worldwide because the data will be freely accessible and not patentable. The project thus aims to make sure that the molecular data of the various tumor types can be used as swiftly as possible for new diagnostic methods or therapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/international-cancer-genome-project-publishes-article-in-nature
Press release - 22/04/2010 Biotechnology is a driver of economic growth The latest economic figures on biotechnology were presented at the German Biotechnology Days held in Berlin on 21st and 22nd April 2010. The figures show that German biotechnology companies have not lost their innovation power despite the global financial crisis. In 2009 the companies RD expenditures of around one billion euros remained at a similar high level to the previous year. The biotechnology industry is creating new jobs despite the…https://www.gesundheitsindustrie-bw.de/en/article/press-release/biotechnology-is-a-driver-of-economic-growth
Article - 19/04/2010 Natural antibodies to treat Alzheimer’s Alzheimers disease is characterised by changes in the substance and structure of the brain that are caused by the depositing of protein plaques in the brain. Prof. Michael Przybylski and his team of researchers at the University of Constance have deciphered the structure of the site where mouse antibodies attach to the plaques subsequently causing them to dissolve. These findings will now be used to identify the binding structure of a component…https://www.gesundheitsindustrie-bw.de/en/article/news/natural-antibodies-to-treat-alzheimer-s
Article - 15/04/2010 Rainer Wittig: oxygen biology opens up new paths “When one talks about light in the field of biology, the crucial role played by oxygen often comes into it.” When Rainer Wittig says that he sees himself as an oxygen researcher, he is not just simplifying his job title because essentially, that is exactly what he is. A lot of the molecular biologist’s work revolves around oxygen, in particular its highly reactive forms. Wittig has been head of the biology department at the Ulm-based ILM since…https://www.gesundheitsindustrie-bw.de/en/article/news/rainer-wittig-oxygen-biology-opens-up-new-paths
Press release - 30/03/2010 Mediagnost GmbH - successfull since 25 years Mediagnost Gesellschaft für Forschung und Herstellung von Diagnostika GmbH in Reutlingen is one of the oldest biotechnology companies in Germany. Mediagnost offers a broad range of services including the production of antibodies proteins and viruses the analysis of samples and the customisation of raw materials. The company celebrated its 25th anniversary on 19th March 2010 with a series of events.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mediagnost-gmbh-successfull-since-25-years
Press release - 26/03/2010 Restarting the muscular engine – Research Prize awarded to two medical practitioners from Ulm and Heidelberg Dr. Karin Jurkat-Rott, associate professor at the Institute of Applied Physiology at the University of Ulm, and Dr. Marc-André Weber, associate professor and chief physician in the Department of Radiology at the Heidelberg University Hospital, were awarded the Eva Luise Köhler Research Prize for Rare Diseases in Berlin on 1st March 2010. The prize was awarded by Luise Köhler in the presence the German Federal President Horst Köhler, the German…https://www.gesundheitsindustrie-bw.de/en/article/press-release/restarting-the-muscular-engine-research-prize-awarded-to-two-medical-practitioners-from-ulm-and-heid
Article - 22/03/2010 IBR Inc.: Dual strategy for safe and effective drugs IBR Inc. a science-based provider of preclinical and clinical services specialises in inflammatory diseases. The analyses it carries out for the pharmaceutical and biotech sector help exclude potential side effects of specific drug candidates early in the development process. https://www.gesundheitsindustrie-bw.de/en/article/news/ibr-inc-dual-strategy-for-safe-and-effective-drugs
Press release - 12/03/2010 mtm laboratories announces the European launch of CINtec® PLUS mtm laboratories, a privately held diagnostics company from Heidelberg, Germany, announced the launch of CINtec® PLUS, the company’s next generation cervical cancer screening product with unmatched accuracy for the screening and management for cervical cancer. CINtec® PLUS will be launched with claims direct in Germany, Italy, Spain, France and the UK, and will also be available in other parts of the world via mtm’s nominated distributors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mtm-laboratories-announces-the-european-launch-of-cintec-plus
Press release - 04/03/2010 New German-Austrian project for breast cancer therapy Hope for breast cancer patients under the leadership of the Vorarlberg Institute for Vascular Investigation and Treatment VIVIT a cross border cooperation is to start between hospitals and bioanalytical laboratories of the Rhine Valley and Lake Constance region. It is aimed at exploring the influence genetic material DNA has on the progression of breast cancer and the response to breast cancer treatment. A collaboration which became possible…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-german-austrian-project-for-breast-cancer-therapy
Article - 22/02/2010 Treasure trove of data from Ulm helps in the understanding of community-acquired pneumonia CAP community-acquired pneumonia is a common type of pneumonia that mainly affects young and old people. In Germany around 800000 people contract CAP every year and almost one third has to be admitted to hospital exceeding the number of admissions due to cardiac infarction or stroke. The CAPNETZ competence network which up until recently was funded by the German government is gradually shedding light on a hitherto little known disease.https://www.gesundheitsindustrie-bw.de/en/article/news/treasure-trove-of-data-from-ulm-helps-in-the-understanding-of-community-acquired-pneumonia
Press release - 18/02/2010 New molecules promise improved diagnosis of pancreatic cancer Being diagnosed with pancreatic cancer is often a death sentence. One reason for the high mortality rate of pancreatic cancer patients is that there is currently no reliable diagnosis of early stages and no cure once the disease has reached a late stage. In an EU-funded project, 23 research groups from six countries have developed new strategies for the improved diagnosis of pancreatic cancer. Researchers at the Ulm-based Hospital for Nuclear…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecules-promise-improved-diagnosis-of-pancreatic-cancer
Press release - 04/02/2010 QIAGEN acquires ESE GmbH QIAGEN N.V. has announced its acquisition of ESE GmbH a privately owned developer and manufacturer of UV and fluorescence optical measurement devices. ESE GmbH is based in Stockach Germany. The cash transaction is valued at up to US19 million.https://www.gesundheitsindustrie-bw.de/en/article/press-release/qiagen-acquires-ese-gmbh
Press release - 04/02/2010 World Cancer Day: encouraging the prevention, detection and treatment of cancer World Cancer Day on the 4th of February is designed to raise awareness that cancer remains one of the major, often fatal human diseases. Every year, more than twelve million people worldwide develop cancer. The Helmholtz Association carries out research into the development of cancer and the underlying risk factors, and comes up with effective strategies for the prevention of cancer and for better diagnostics and targeted therapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/world-cancer-day-encouraging-the-prevention-detection-and-treatment-of-cancer
Press release - 28/01/2010 Roche invests 86 million Swiss Francs in its Mannheim site Roche is to invest 86 million Swiss Francs (approximately 57.3 million euros) in the construction of a new pharmaceutical production unit at its Mannheim company site. The new production line will deliver the commercial supply of the breast cancer drug Herceptin (trastuzumab) from 2013 onwards.https://www.gesundheitsindustrie-bw.de/en/article/press-release/roche-invests-86-million-swiss-francs-in-its-mannheim-site
Press release - 26/01/2010 MicroTEC Südwest convinces in the second round of the BMBF’s Leading Edge Cluster competition The winners of the second round of the German Federal Ministry of Education and Research’s (BMBF) Leading Edge Cluster competition have now been selected. On 26th January 2010, the chairman of the jury, Prof. Dr. Andreas Barner (spokesperson for the Boehringer Ingelheim GmbH Management Board), and the German Research Minister, Prof. Dr. Annette Schavan, announced in Berlin which of the ten finalists of the highly lucrative Leading Edge Cluster…https://www.gesundheitsindustrie-bw.de/en/article/press-release/microtec-suedwest-convinces-in-the-second-round-of-the-bmbf-s-leading-edge-cluster-competition
Article - 25/01/2010 Treatment and Research Centre of Rare Diseases established in Tübingen On 22nd January 2010, the first German Treatment and Research Centre of Rare Diseases (ZSE) was officially opened in Tübingen. Interdisciplinary teams will from now on be developing new therapies under one roof for around three to four million patients suffering from rare diseases in Germany. The centre in Tübingen will offer optimal patient treatment, coordinate the cooperation between international specialists, and provide competent advice and…https://www.gesundheitsindustrie-bw.de/en/article/news/treatment-and-research-centre-of-rare-diseases-established-in-tuebingen
Article - 25/01/2010 Intelligent use of suitable biomarkers How quickly does a pharmaceutical substance exert its effect? What mechanisms does it use to exert its effect on people and how long does it remain active? In a team headed by Prof. Dr. Martin Elmlinger Nycomed GmbH has developed an efficient biomarker discovery concept specially adapted to the companys requirements and designed to clarify such questions. The concept is specifically geared to the phases and requirements of the companys projects.…https://www.gesundheitsindustrie-bw.de/en/article/news/intelligent-use-of-suitable-biomarkers
Press release - 18/01/2010 Measurement instead of culture – rapid detection of Legionella There has been an unusually high frequency of Legionella infections in the city of Ulm in the period since mid-December 2009. The search for the source of the infection is well underway, although the use of traditional detection methods make it a time-consuming process. New screening methods developed by the Fraunhofer IPM could considerably reduce the time required to detect the source of infection.https://www.gesundheitsindustrie-bw.de/en/article/press-release/measurement-instead-of-culture-rapid-detection-of-legionella
Article - 14/12/2009 Clever surveillance system keeps yeast in check The spectrum of human diseases (mycoses) caused by fungi ranges from trivial nail infections to life-threatening systemic infections. The latter are mainly caused by Candida albicans. The dermatologist Prof. Dr. med. Martin Schaller from Tübingen is investigating how this fungus, which is actually part of the normal microbial flora of humans, becomes a pathogen. At the same time, he is looking into the role the patient’s immune system plays in…https://www.gesundheitsindustrie-bw.de/en/article/news/clever-surveillance-system-keeps-yeast-in-check
Press release - 08/12/2009 Official opening of the BioRN Academy in Mannheim On 7th December 2009, the BioRN Academy was opened with an official ceremony at the MAFINEX Technology Centre in Mannheim, Germany. This marks the beginning of a project, which is the only one of its kind in Germany, aimed at the further qualification of life scientists as managers in the biotechnology industry. The Rhine-Neckar Graduate School, Graf & Associate, Roche Diagnostics and the SRH University of Applied Sciences Heidelberg are all…https://www.gesundheitsindustrie-bw.de/en/article/press-release/official-opening-of-the-biorn-academy-in-mannheim
Press release - 07/12/2009 Curetis AG - € 18.5 million Series A Financing Round closed A consortium of leading life-science venture capital funds invests € 18.5 million in the German medical diagnostics company Curetis AG. This financing will enable Curetis to complete development of its innovative diagnostic products through to market entry.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-18-5-million-series-a-financing-round-closed
Article - 30/11/2009 BioPharMaXX cluster to strengthen the Ulm region BioRegionUlm recently announced the launch of BioPharMaXX at a meeting held in Ummendorf castle (close to Ulm). The acronym refers to a cluster focusing on biotechnology, pharmacy and medical technology that was selected as one of twelve regional clusters in a state-wide contest in Baden-Württemberg in 2008. Company representatives and researchers presented projects to improve the time-consuming and costly protein purification process used in…https://www.gesundheitsindustrie-bw.de/en/article/news/biopharmaxx-cluster-to-strengthen-the-ulm-region
Article - 28/11/2009 "You cannot afford to fail twice in Germany" Prof. Dr. Bodo Liedvogel and Dr. Heinz Haubruck founded the company DIARECT AG in Freiburg in 1998. They not only brought 20 years of experience in industry to the company but also their entire savings. In the following interview Dr. Heinz Haubruck tells Christoph Bächtle about the return investors expect from companies how to win over potential clients and the risks associated with setting up ones own business.https://www.gesundheitsindustrie-bw.de/en/article/news/you-cannot-afford-to-fail-twice-in-germany
Press release - 24/11/2009 Three new collaborative research centres in Baden-Württemberg The German Research Foundation (DFG) is set to establish 17 new collaborative research centres (SFBs) on 1st January 2010. Ten of the new SFBs will focus on life science research projects, and will initially be funded for a period of four years with a total of 78 million euros in funding. One of the SFBs will be established at the University of Freiburg. Six of the 17 new SFBs are SFB/Transregio projects involving researchers from several German…https://www.gesundheitsindustrie-bw.de/en/article/press-release/three-new-collaborative-research-centres-in-baden-wuerttemberg
Press release - 23/11/2009 GATC Biotech soon opens sequencing laboratory in London GATC Biotech Europes leading sequencing service provider for industrial and academic research announces that it will open a sequencing laboratory in London to provide scientists in UK and Ireland with single sample sequencing services. The GATC London Laboratory will be situated in the London BioScience Innovation Centre LBIC and will start operations on January 4 2010. https://www.gesundheitsindustrie-bw.de/en/article/press-release/gatc-biotech-soon-opens-sequencing-laboratory-in-london
Article - 05/11/2009 CLAIR provides new insights The human eye is a fascinating organ as well as model for the specialists at Stockach-based Sensovation AG. Their complex optical detection systems are based on CCD and CMOS technologies. However a high-tech sensor is able to recognise much more than many eyes put together. https://www.gesundheitsindustrie-bw.de/en/article/news/clair-provides-new-insights
Press release - 27/10/2009 Precision Diagnosis of Brain Tumors: Antibody to Detect Enzyme Defect More than 100 different types of brain tumor are known in medicine. Their exact diagnosis is often difficult, because only tiny amounts of tumor tissue are usually available. Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the University of Heidelberg have developed an antibody which is highly specific for the characteristic alteration of an enzyme that is typical of two dangerous types of brain tumor.…https://www.gesundheitsindustrie-bw.de/en/article/press-release/precision-diagnosis-of-brain-tumors-antibody-to-detect-enzyme-defect
Press release - 20/10/2009 2nd Science to Market Conference The second Science to Market Conference took place in Hannover, Germany, on October 6 – 7, 2009. The aim of the conference was the promotion of cooperation between academia and industry in the area of pharmaceutical biotechnology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/2nd-science-to-market-conference
Press release - 14/10/2009 mtm laboratories Extends Series C Financing Round by EUR 7 Million Bringing Total to EUR 39 Million (USD 57 Million) mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, announced on 14th October the signing for an additional tranche of Euro 7 million to its Series C funding. This addition is a formal expansion of the Company’s last Series C in March 2008 and increases the total for the round to Euro 39 million (USD 57 million) in…https://www.gesundheitsindustrie-bw.de/en/article/press-release/mtm-laboratories-extends-series-c-financing-round-by-eur-7-million-bringing-total-to-eur-39-million
Press release - 30/09/2009 New managing director for BioRegion Rhein-Neckar-Dreieck e.V. Biotech expert Dr. Julia Schüler is leaving Ernst Young to join BioRegion Rhein-Neckar-Dreieck e.V. Rhine-Neckar BioRegion. The biologist is to succeed Ernst-Dieter Jarasch the associations managing director since its establishment in 1996.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-managing-director-for-bioregion-rhein-neckar-dreieck-e-v
Press release - 24/09/2009 CeGAT: Tracking genes using cutting-edge technologies To adequately meet the growing demand for genetic diagnostics doctor scientist and bioinformatician Dr. Saskia Biskup and her husband business graduate Dr. Dirk Biskup founded the Center for Genomics and Transcriptomics or CeGAT for short in July 2009. As a supplier of DNA and RNA sequencing in the STERN BioRegion CeGAT which is based in the Technology park Tübingen Reutlingen TTR uses state-of-the-art high-throughput technologies to examine…https://www.gesundheitsindustrie-bw.de/en/article/press-release/cegat-tracking-genes-using-cutting-edge-technologies
Press release - 18/09/2009 Why don’t brain tumours respond to drugs? Malignant brain tumours do not often respond to promising new drugs. Researchers from Heidelberg have now uncovered a mechanism and a tumour marker that are linked to the development of this resistance. A “death receptor” might possibly indicate the chances of success of chemotherapy at the same time as providing new approaches for developing a new therapy for the successful treatment of brain tumours.https://www.gesundheitsindustrie-bw.de/en/article/press-release/why-don-t-brain-tumours-respond-to-drugs
Press release - 14/09/2009 Launch of SAFE-T Consortium: Translational Safety Biomarkers "Faster Development of Safer Medicines through Translational Safety Biomarkers": On September 14, 2009, the Safer And Faster Evidence-based Translation (SAFE-T) consortium project under the EU Innovative Medicines Initiative - Joint Undertaking (IMI-JU) was presented at the EUROTOX 2009 conference in Dresden. The consortium announces the start of work to qualify biomarkers for drug-induced kidney, liver and vascular injury in…https://www.gesundheitsindustrie-bw.de/en/article/press-release/launch-of-safe-t-consortium-translational-safety-biomarkers
Article - 14/09/2009 SensScreen Technologies: Magnetic separation to conquer biotechnological areas of application In terms of protein purification, the biopharmaceutical industry is increasingly reaching its technical and economic limits. The currently used chromatography procedures are expensive, time-consuming and associated with high product losses due to the large number of individual processing steps involved. Special magnetic microparticles, such as those developed by the chemist Dr. Jochen F. Peter with his recently established company SensScreen…https://www.gesundheitsindustrie-bw.de/en/article/news/sensscreen-technologies-magnetic-separation-to-conquer-biotechnological-areas-of-application
Article - 03/09/2009 Company establishment with combined forces The company DSL a specialist in molecular diagnostics is currently being established in the city of Eriskirch close to Friedrichshafen Germany. The future managing directors Dr. Sabine Lautenschläger and Dr. Daniel Schaarschmidt are being supported by the BioLAGO network and the pharmaceutical company Nycomed.https://www.gesundheitsindustrie-bw.de/en/article/news/company-establishment-with-combined-forces
Article - 12/08/2009 More effective extraction of small RNAs Small RNAs are gaining in importance in research as well as in the biotechnology and pharmaceutical industries. However the potential of these molecules can only be exploited fully if very pure RNAs can be extracted from the cells in sufficiently high quantities. Currently used methods are expensive and only designed for large cell quantities. In addition the operation of the extraction systems is very complicated. A new biochip developed by Dr.…https://www.gesundheitsindustrie-bw.de/en/article/news/more-effective-extraction-of-small-rnas
Press release - 10/08/2009 Biomarkers help predict the risk of Alzheimer’s in patients with mild cognitive impairment A large multicentre study has shown that CSF (cerebrospinal fluid) biomarkers can be used to predict, with good accuracy, as to which patients with mild cognitive impairments will develop Alzheimer’s disease. The biomarkers used are microtubule-associated proteins that are abundant in CNS neurons as well as beta amyloid, which is a peptide that forms brain plaques in people with Alzheimer’s disease. Changes in the concentrations of these proteins…https://www.gesundheitsindustrie-bw.de/en/article/press-release/biomarkers-help-predict-the-risk-of-alzheimer-s-in-patients-with-mild-cognitive-impairment
Article - 06/08/2009 PEPperPRINT wins award for its peptide chips PEPperPRINT GmbH, a spin-off of the German Cancer Research Centre, has won the Science4Life Venture Cup, a German start-up contest that comes with the most prize money. The Heidelberg-based start-up company was previously awarded the renowned research prize by the German Stifterverband and was chosen as a “Landmark in the Land of Ideas” competition run by the German government in 2009.https://www.gesundheitsindustrie-bw.de/en/article/news/pepperprint-wins-award-for-its-peptide-chips
Article - 30/07/2009 Dragnet investigation for substance killers The Ulm-based company Labor Dr. Merk Kollegen with over 40 employees is a specialist company identifying foreign bodies such as viruses bacteria and toxins in biopharmaceuticals and medical products. In addition the medium-sized company has been developing producing and marketing diagnostics for medical use for almost 40 years.https://www.gesundheitsindustrie-bw.de/en/article/news/dragnet-investigation-for-substance-killers
Press release - 28/07/2009 Fostering enthusiasm for successful entrepreneurship BioRegio STERN Management GmbH has honoured the winning projects in the regional “Science2Start” competition. A panel of experts awarded a total of 2,250 euros for the most innovative ideas with marketing potential. The winners celebrated their success with approx. 240 visitors of the annual summer event jointly organised by BioRegio STERN Management GmbH, the Society for the Promotion of Biotechnology Stuttgart/Tübingen/Neckar-Alb e.V. and PUSH!…https://www.gesundheitsindustrie-bw.de/en/article/press-release/fostering-enthusiasm-for-successful-entrepreneurship
Dossier - 16/07/2009 Patents – the exploitations of inventions in the life sciences According to statistics from the European Patent Office a total of 1065 biotechnological patents were filed in 2007 by inventors based in Germany. This puts Germany second behind the USA. In the coming years experts expect that a much larger number of biotech patents will be filed. For life sciences inventors the registration of patents quite often represents a real challenge. People entering the world of patents and licences are faced with a…https://www.gesundheitsindustrie-bw.de/en/article/dossier/patents-the-exploitations-of-inventions-in-the-life-sciences
Press release - 07/07/2009 Investment in the future: ILM receives funds for the purchase of equipment The Ulm-based Institute for Laser Technologies in Medicine and Metrology (ILM) has received a 335,000 euro injection in 2009 through the German government’s Future Investment Programme (Economic Stimulus Packet II), according to the Baden-Württemberg Minister of Economic Affairs Ernst Pfister. The funds, 75 per cent of which are provided by the German government and 25 per cent by the state of Baden-Württemberg, will be used for the modernisation…https://www.gesundheitsindustrie-bw.de/en/article/press-release/investment-in-the-future-ilm-receives-funds-for-the-purchase-of-equipment
Article - 02/07/2009 A virus that hides while it waits for an opportunity to replicate Thomas Mertens, Medical Director of the Institute of Virology in Ulm, has a strong scientific and clinical interest in the human cytomegalovirus (HCMV), a big virus with a big impact which, despite its size, is overshadowed by known viruses such as the HI virus that is the object of research for Mertens’ colleagues. HCMV research is a challenging area where quick successes are rare.https://www.gesundheitsindustrie-bw.de/en/article/news/a-virus-that-hides-while-it-waits-for-an-opportunity-to-replicate
Press release - 30/06/2009 febit First to Offer Newly Published Mouse Genome on a Chip for DNA/RNA Detection and Enrichment In the near future, Next-Generation Sequencing technologies will lead to a rising number of completed genomes of model organisms and other species of interest, as demonstrated by the updated mouse genome. This accelerated development will generate a variety of tools available in the short term for the application of the new data into experiments. febit’s technology enables the conversion of new sequence data into biochips for gene expression…https://www.gesundheitsindustrie-bw.de/en/article/press-release/febit-first-to-offer-newly-published-mouse-genome-on-a-chip-for-dna-rna-detection-and-enrichment
Article - 29/06/2009 Alternative protein structures and breast cancer A single protein can have many variants. This variability is achieved by a process known as splicing which can introduce small modifications into the mRNA transcript of a gene. Prof. Dr. Elmar Stickeler from the University Womens Hospital in Freiburg found that some of these splice variants can also induce cancer. Stickeler and his team are investigating how splicing factors change their target molecules and how this leads to breast cancer. This…https://www.gesundheitsindustrie-bw.de/en/article/news/alternative-protein-structures-and-breast-cancer
Press release - 29/06/2009 Can loss of sense of smell predict Alzheimer’s The first lapses of memory go hand in hand with a loss of the sense of smell: The olfactory centre in the brain of Alzheimer’s patients is wasting away. The olfactory bulb starts to shrink at a very early stage of the disease, at a time when retentiveness is only slightly affected. It is possible to detect the shrinkage of the olfactory bulb with magnetic resonance imaging, as the latest findings by scientists of the Department of Psychiatry at…https://www.gesundheitsindustrie-bw.de/en/article/press-release/can-loss-of-sense-of-smell-predict-alzheimer-s
Press release - 22/06/2009 MRI for tracing living cells Researchers from the Mannheim Medical Faculty which is part of Heidelberg University and the Max Planck Institute MPI for Biological Cybernetics in Tübingen have achieved a world first in the use of magnetic resonance imaging MRI for the simultaneous visualisation of sodium and potassium ions which are important for proper cell function in the living cell. The scientists from the Mannheim Medical Faculty have thus achieved an important milestone…https://www.gesundheitsindustrie-bw.de/en/article/press-release/mri-for-tracing-living-cells
Press release - 22/06/2009 Successful start: cooperative projects of the Rhine-Neckar Biotechnology Cluster (BioRN) The first joint public appearance of the numerous players of the BioRN top cluster underlines the importance of cooperations between industry and science. At the first annual BioRN conference the Cell-based and molecular medicine top cluster announced the successful start of five cooperative projects funded by the German Federal Ministry of Education and Research. In a strategy workshop the companies involved in the projects presented all 36…https://www.gesundheitsindustrie-bw.de/en/article/press-release/successful-start-cooperative-projects-of-the-rhine-neckar-biotechnology-cluster-biorn
Press release - 10/06/2009 6.56 million euros for first full-body PET-MRI prototype The Joint Science Conference in Bonn has announced that the University of Tübingen will receive 6.56 million euros for the purchase of an entirely new multimodal full-body tomography system for the diagnosis of cancer. The new full-body PET-MRI combines positron emission tomography PET with magnetic resonance imaging MRI in one device.https://www.gesundheitsindustrie-bw.de/en/article/press-release/6-56-million-euros-for-first-full-body-pet-mri-prototype